Call Us Today
+44 (0) 20 7088 8240
+44 (0) 20 7088 8240
How the product is processed and sold matters more than how much is grown. Our processing strategy is designed to capture the maximum value from every kilogram of flower.
Our GACP certification covers the agricultural phase of production. To reach EU pharmacy shelves, product must pass through a GMP-certified processing facility. In the near term, we work with established European GMP-certified processing partners. Our target is to achieve our own EU-GMP certification by the end of 2026 with the completion of our dedicated processing facility — bringing the full value chain in-house.
Instead of selling flower outright to a contract manufacturer, we pay a partner GMP-certified facility to process on a fee basis and retain ownership of the finished product. We then sell directly to German and EU distributors at pharmaceutical wholesale prices. This approximately doubles revenue per batch compared to outright CMO sales. Once our own GMP facility is operational by end of 2026, we capture the full margin in-house.
Rosin is extracted using heat and pressure alone, producing a pharmaceutical-grade concentrate with zero residual solvents. It commands a significant premium over dried flower, has a cleaner regulatory profile, and is increasingly preferred by clinicians and patients for formulation into capsules, tinctures and topicals.
We are in active discussions with established EU GMP-certified processing and distribution partners with proven German market access and multi-market capability. These partnerships provide our route to market while we build towards our own GMP certification.
The flower is the starting point. The extract is where the value lives. Retained ownership is how we keep it.
Yes. Medical cannabis has been legal in the UK since November 2018 following changes introduced after high-profile cases like that of Alfie Dingley. However, access is tightly regulated and prescriptions are typically issued by specialist doctors. Frontier Botanics operates fully within UK and international legal frameworks to ensure compliance at every stage of production and distribution.
Lesotho was the first African nation to legalise medical cannabis cultivation and export, offering a stable regulatory environment, favourable climate, and cost-efficient production conditions. This allows Frontier Botanics to produce high-quality, pharmaceutical-grade cannabis at scale while maintaining competitive pricing for international markets.
Frontier Botanics focuses on vertically integrated operations—from cultivation in Lesotho to distribution in the UK—ensuring full control over quality, compliance, and supply chain efficiency. The company combines pharmaceutical standards with scalable infrastructure, positioning itself to meet growing demand in regulated global markets.
Frontier Botanics is currently raising capital to expand cultivation capacity, enhance processing facilities, and secure additional distribution partnerships. The funding round is designed to accelerate growth, increase production output, and strengthen the company’s position within the rapidly expanding global medical cannabis market.
The global medical cannabis market is projected to grow significantly over the coming decade, driven by increasing legalisation, patient demand, and clinical research. Countries across Europe—including the UK—are gradually expanding access, creating a strong long-term growth opportunity for early-stage, compliant operators like Frontier Botanics.
Cultivating Growth. Delivering Global Medical Cannabis Excellence.
New Frontier Holdings Ltd
First Floor 690 Great West Road, Osterley Village, Isleworth, England TW7 4PU
Company No. 12111072
England & Wales
Frontier Botanics Lesotho (Proprietary) Limited, Morena Khoase Kolobe, Mohalalitoe Road Maseru, Kingdom of Lesotho
© 2026 New Frontier Holdings Ltd.
